Definitive Contract 75A50123C00050
Award Date
9/15/23
Potential Completion Date
12/31/29
Potential Value
$167M
Awardee
Venatorx Pharmaceuticals Inc.
Ultimate Awardee
Not listed
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Sharing
Place of Performance
Malvern, PA 19355, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $44,247,749 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Venatorx Pharmaceuticals Inc. (doing business as Venatorx) for the development of a novel beta-lactamase inhibitor targeting multidrug-resistant Acinetobacter baumannii. This contract is not set aside and was awarded through full and open competition. Venatorx is a biopharmaceutical company...
The Defense Threat Reduction Agency awarded a $19,969,099.47 cost-plus-fixed-fee definitive contract to Venatorx Pharmaceuticals Inc. (doing business as Venatorx) for the research, development, and manufacturing of penicillin binding proteins. The contract does not have a set-aside designation and has a completion date of October 27, 2023. Venatorx, a for-profit organization, has a history of receiving federal contracts and grants from agencies such as the Department of Health and Human Services...
<p>This is a $98,144,230.00 definitive, cost-sharing contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to The Medicines Company on September 15, 2016. The contract is to advance the development of a portfolio of anti-infective programs. There is no set-aside designation indicated. The contract has an ultimate completion date of September 30, 2030.</p>
This is a $237,994,127.86 definitive cost-reimbursement contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response to Hoffmann-La Roche Inc. for the "COMBATING MULTI-DRUG RESISTANCE AND ADDRESSING EMERGING BACTERIAL THREATS: DISCOVERY, CLINICAL DEVEL" program. The contract has a period of performance through September 30, 2027 and does not have a set-aside designation. The contract supports the agency's efforts to...
This is a $27,032,719.27 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Spero Therapeutics, Inc. to advance the clinical and non-clinical development of an antibiotic candidate. The contract is not set aside. The contract originated from a NIAID Broad Agency Announcement (BAA) soliciting proposals for the advanced development of vaccine candidates, therapeutic products, and diagnostics to address biodefense, antimicrobial...
This federal contract award, valued at up to $114,146,088.00, was issued by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Vedanta Biosciences, Inc., a biotechnology company. The contract was awarded under a Broad Agency Announcement (BAA) solicitation from BARDA (Biomedical Advanced Research and Development Authority) that sought proposals for the advanced research and development of medical countermeasures against...
This is a $26,427,820.00 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Revagenix Inc. The contract is for the advanced development of a novel LPXC inhibitor with pan-resistant Pseudomonas and Burkholderia activity. This contract was awarded under a Broad Agency Announcement (BAA) solicitation that sought proposals for research and development of vaccines, therapeutics, and diagnostics...
This federal contract award, valued at $142,964,968.00, was issued by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Melinta Therapeutics, LLC, a for-profit limited liability company and manufacturer of pharmaceutical goods. The contract is a definitive cost-sharing agreement that aims to advance the development of two antibiotics for use in the pediatric population to treat serious bacterial infections where multidrug-resistant organisms are common....
This is a definitive cost-sharing contract awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) to Locus Biosciences Inc., a clinical-stage biopharmaceutical company, for the clinical development of a CRISPR-Cas3 phage cocktail to treat recurrent urinary tract infections caused by Escherichia coli, including antimicrobial and multi-drug resistant strains. The contract has a ceiling value of $91,817,550.73 and a completion...
This $18,274,778 definitive contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to AN2 Therapeutics, Inc. The contract supports the development of epetraborole as a novel therapeutic for melioidosis and additional antimicrobial resistant bacterial biothreat pathogens. This award was issued under a Broad Agency Announcement (BAA) that also sought proposals for advanced vaccine and diagnostic development against biodefense and emerging...